Answers are grounded in this paper and cite their sources.
Reviews cardiovascular risks and xanthine oxidase inhibition in gout, highlighting comparative safety outcomes between febuxostat and allopurinol.
Gout, a chronic rheumatologic illness characterized by hyperuricemia, arthritis, tophaceous deposits, and renal calculi, is associated with increased rates of cardiovascular and chronic kidney disease. 1 Prospective observational studies have shown that the risk of cardiovascular mortality is higher in people with gout and coronary heart disease compared with those with coronary disease who do not have gout. 2 Epidemiological associations among hyperuricemia, gout, and risk factors for cardiovascular disease are robust, 3 but whether hyperuricemia and gout are independent risk factors for coronary disease remains controversial.Urate has a complex relationship to oxidative stress, possessing both scavenging properties as well as oxidizing and radical-forming properties. 4,5These data have led to small, interventional studies that have shown that urate-lowering agents such as allopurinol may improve a number of cardiovascular conditions, including heart failure, 6 hypertension, 7 and chronic kidney disease. 8he xanthine oxidase inhibitors are the mainstay of therapy for reducing serum urate levels in patients with gout.The xanthine oxidase inhibitor allopurinol was approved in 1966, and febuxostat, a nonpurine inhibitor of xanthine oxidase, was approved for the management of hyperuricemia in patients with gout in 2009.Allopurinol and its metabolites are structural analogues of both purines and pyrimidine compounds and thus can affect enzymes in both metabolic pathways, whereas febuxostat is a nonpurine inhibitor of only xanthine oxidase. 9In clinical practice, the pharmacological advantages of febuxostat over the commonly used doses of allopurinol have included greater serum urate-lowering efficacy, fewer reported severe hypersensitivity reactions, and no requirement for dose adjustment in patients with moderate renal impairment, a common comorbidity in gout. 1,9uring the development of febuxostat, this drug was compared to placebo and allopurinol in clinical trials involving >5000 patients with gout. 9,10These studies showed a small imbalance in the rates of major cardiovascular events occurring at 0.74 per 100 patient-years with febuxostat versus 0.60 per 100 patient-years with allopurinol.The US Food and Drug Administration approved febuxostat with the contingency that a large cardiovascular safety outcome study be performed to determine its cardiovascular profile compared to allopurinol in patients with gout.This study, the CARES trial (Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities), was conducted between 2010 and 2017 to determine whether febuxostat was noninferior to allopurinol on major cardiovascular events in patients with gout and cardiovascular disease. 11he study population for the CARES trial was limited to patients with gout who had prior evidence of cardiovascular disease, a strategy previously used in the US Food and Drug Administration-mandated cardiovascular safety studies in diabetes
No takes yet. Share an insight, caveat, or question.
William B. White (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: